In 2020, Liu et al. [14] indicated that β-elemene might lower m6A modification levels in gefitinib-resistant cancer cells by inhibiting METTL3 and provided a molecular docking analysis using AutoDock tools, demonstrating the binding complex of β-elemene with METTL3, where β-elemene occupied the SAM binding site. The gene discussed is METTL3; the disease is cancer.